Index

a
abdominal X-ray of resonance metallic ureteral stent, 93–94
acute infectious obstruction
clinical parameters, 270
fiscal calculations, 269
intention-to-treat analysis, 270
patient parameters, 269
patient presentations, 270
quality of life, 271
renal de-obstruction, 268
systemic inflammatory response syndrome criteria, 267–268
trials, 269
ureteral calculi related obstruction, 267
urosepsis, 267, 270
allium removal, 206
allium stent, 113–115, 196–197
American private healthcare system, 290
anatomical imaging, 18
anatomic variation
duplex ureter, 11
ectopic ureter, 12
horseshoe kidney, 10–11
megaloureter, 11–12
ureterocele, 12–13
antegrade metallic stents, 64
antegrade pyelography, 18
antegrade stenting, indications for, 55–56
antegrade stent insertion, patient preparation for complications, 58–60
contra-indications, 57
pre-procedure, 56–57
procedure, 57–58
antibiotic coatings, 104–105
antibiotic prophylaxis, 210
anti-reflux stent, 96–97
autologous and engineered tissue, 88

b
bacterial-associated encrustation, 215–216
Bard Inlay® stent, 94–95, 103, 241
bare metal stent (BMS), 106
benign ureteric obstruction, ethical issues in, 132
bilateral subcutaneous extra-anatomic stent, 149–150
biodegradable antegrade stents, 64
biodegradable materials, 88
biodegradable ureteric stents advantage, 182
benefits, 187–188
future directions, 187
material, 183
research, 183–185
Temporary Ureteral Drainage Stent™, 185
Uriprene™, 186–187
biomaterials, 84
“blind” stent insertions, 125
Boari flap, 282–283
Boston Scientific dual durometer stent, 94–95

C
C-flex, 86
chlorhexidine, 105
chronic obstructive uropathy, 289–290
Chronoflex, 86
clarithromycin-coated stents, 104
coated and drug-eluting stents
drug-eluting stents, 105–106
encrusted distal curl of ureteral stent, 102–103
stent coatings, 102–105
coated metallic stents (CMSs), 296
concept, 113
urology, 113–115
coatings, 87–88
coaxial dilators, 140–142
computed tomography (CT), 18
congenital megareter, 12
congenital variations, 4–6
CONSORT, 266
contrast, 143
Cook Resonance stent, 93
cystoscope, 136–137
d
DESSs. see drug-eluting stents (DESs)
detour extra-anatomical ureteric stent, 160
algorithm, 172–173
alternative techniques, 172
experience with detour stent, 169–170
experience with JJ stent, 166–169
hollow plastic dilator, 164
infection, 172
need for an extra-anatomic drainage, 164–166
Paterson-Forrester stent, 161–162
personal experience, 170–171
prerequisites, 166–167
recurrent obstruction, 172
removal, 208
technique, 171
Teflon-coated section, 161, 163
32F Amplatz sheath, 161, 163
diamond-like carbon, 103–104
dissolvable stent, 96
double J stent, 78–79
double-lumen stent, 96
double pigtail stents, 94
drug-eluting biodegradable stents, 297
drug-eluting stents (DESs), 81
chlorhexidine, 105
concept, 111
design and structure of, 111
ketorolac, 105
metal drug-eluting stents, 106
pharmaceutical substances, 111
triclosan, 105
urology, 111–113
dual-durometer stent, 94
dual-lumen ureteric catheter, 126, 142
duplex ureter, 5–7, 11
e
ectopic and retrocaval kidney, 49
ectopic ureter, 12
ectopic ureteric orifice, 7
embryology, 4–6
emergency management
comparative effectiveness, 70–71
drainage modality, 72
outcomes by drainage modality, 68–69
patients with obstructive pyelonephritis, 68
pyonephrosis, 67
quality of life, 71
uro lithiasis, 67
encrustation of indwelling urinary devices
bacterial-associated encrustation, 215–216
non-bacterial based indwelling device encrustation, 217–218
non-bacterial causes, 216–217
prevention, 218
stent coatings, 218–223
encrusted stent removal, 209–210
endometriosis and tuberculosis, 51
endothelial hyperplasia, 199
endothelin-1 (ET-1), 21
engineered biodegradable coronary stents, 187
equipment and technical considerations
coaxial dilators, 140–142
contrast, 143
cystoscope, 136–137
dual-lumen catheter, 142
fluoroscopy, 137
guidewires, 137–139
high-pressure catheters and balloon dilators, 143
“Hockey Stick” KMP/Imager II catheters, 144
equipment and technical considerations (cont'd)
tips and tricks, 146
ureteral catheters, 140–141
ureteral stent, 144–146
ethical issues
benign ureteric obstruction, 132
clinical presentation, 131
considerations, 133
multidisciplinary approach, 133
palliative care teams, 132
patient desire, 132
patient status, family and social issues, 132
salvage therapy options, 131
upper tract obstruction, 130
etiology of ureteric obstruction
congenital causes, 48–49
inflammatory causes, 50–51
metabolic causes, 49–50
neoplastic causes, 50
pregnancy, 52
retroperitoneal fibrosis, 51–52
EuroQol utility values, 288
evidence base
endourology, 264
evidence-based medicine primer, 264–265
meta-analysis and systematic reviews, 267
randomized controlled trials, 265–267
treatment of acute infectious obstruction, 267–271
tubeless percutaneous nephrolithotomy, 274–275
ureteroscopy and post-procedure stent insertion, 271–274
evidence-based medicine (EBM), 264–265
extra-anatomical stent removal, 208
extra-anatomic JJ stent
bilateral extra anatomic Detour stents, 166, 168
CT scan, 169
50 cm 8FG double-pigtail stent, 166
ileostomy bag, 166–167
nephrostomy puncture, 166, 168
silicone tubes, 166–167
extra-anatomic stent urinary bypass
bilateral subcutaneous extra-anatomic stent, 149–150
complications, 157–159
contraindications, 151
future developments, 160
indications, 150–151
kinking, 149–150
lower aspect of stent insertion procedure, 155–156
Paterson Forrester stent, 151–152
stent placement, 152–153
technique of stent changes, 155–157
top end aspect of stent insertion procedure, 153–154
tunneling procedure, 154–155
unilateral subcutaneous stent, 149–150
extra-corpooreal shockwave lithotripsy (ESWL), 30, 229
f
film-anchoring stent, 98
fluoroscopy, 137
forgotten JJ stents
lack of stent tracking systems, 120
left PCNL, 120, 122
major problem, 122
obstructive uropathy, 120–121
stone disease, 120–121
trends in management of, 122–125
forgotten stents, 296
4.7 F double-J stent, 98
4.7 F double pigtail ureteral stents, 178
14/7Fr endopyelotomy stent, 96
8FG Flexima 24 cm Boston Scientific stent, 149
g
Gibbons stent, 78–79
glucagon, 36–37
glycosaminoglycans (GAGs), 104
guidewires, 137–139
G100X-15LB, 183
G100X-20LB, 183
h
health-related quality of life (HRQoL)
development of USSQ, 239–240
patient morbidity, 238
pharmacological agents, 241
position of the distal end of the stent, 242
stent designs and materials, 240–241
stent/patient factors, 238
stent-related symptoms, 238
USSQ for when stented, 242, 253–261
USSQ for when stent in situ, 242–252
high-pressure catheters and balloon dilators, 143
history and evolution of ureteral stents advances in technology, 80–81
ancient history, 76–77
patent activity, 75–76
recent history, 77–80
stent nomenclature, 75–76
“Hockey Stick” KMP/Imager II catheters, 144
horse-shoe kidney (HSK), 4, 6, 10–11
human ureter anatomy
  blood supply, 1–4
  clinical significance, 8
  congenital variations, 4–6
duplex, 5–7
ectopic ureteric orifice, 7
embryology, 4–6
mega-ureter, 8
nerves, 4
PUJ obstruction, 6–7
schematic, 1–2
structure, 3
ureteric diverticulae, 8
ureteroceles, 8
hydrogel-coated stents, 87
hydrophilic coatings, 102–103
hydrophilic straight soft and stiff guide-wires, 138
hydrothane, 86

i
ileal conduit stent removal, 210
illuminating stent removal, 208
impacted metallic stents, 199–200
index stone patient, 271
indwelling ureteric stents
  chronic obstructive uropathy, 289–290
  health economic considerations, 294
health economic evaluations, 287–288
intra-ureteric stents, 292
mean indwelling time, 291
nephrostomy and stenting, 290–291
non-elective cystoscopy, 291
renal transplant, 293–294
short-term application, 288–289
ureteric stent extraction, post-procedural considerations and cost, 292–293
inflammatory cytokines, 21
Inlay®, 86, 92
Inlay Optima®, 86
interventional radiologist, role of
  antegrade metallic stents, 64
  biodegradable antegrade stents, 64
  indications for antegrade stenting, 55–56
  one-stage antegrade stent, 61–62
  patient preparation for antegrade stent insertion, 56–60
  rendezvous procedure, 62–64
  stent design, 60–61
intra-ureteric stents, 292
iontophoresis, 222

j
JJ stents, in India
  common indication of usage, 118–119
  forgotten stents, 120–122
  management of migrated and misplaced stents, 126
  outside the ureter and pelvicalyceal system, 125
  problems, 122
  repositioning of incorrectly placed stents, 126–128
  stent placement, 119
  stent register, 120
  stent tracking and removal, 120
  stent types and economics, 119–120
  trends in management of forgotten stent, 122–125

k
ketorolac, 105

l
L-lactide-glycolidic acid co-polymer stent, 221
Index

**m**
- medical expulsive therapy, 30
- megaureter, 8, 11–12
- Memokath 051, 97, 194–196
- Memokath stents
  - removal, 205–207
  - stent migration, 233
- Memotherm, 194
- metal drug-eluting stents, 106
- metallic ureteric stents, 87, 176, 296
  - allium stent, 196–197
  - corrosion, 192
  - cost, 200
- encrustation, 199
- endothelial hyperplasia, 199
- gold plates, 192
- impacted metallic stents, 199–200
- Memokath 051, 194–196
- Memotherm, 194
- migration, 199
- Passager stent, 198
- Prostakath stent, 193
- Resonance stent, 196
- stainless steel, 193
- status of, 200
- stent migration, 234
- Urolume prostatic stent, 193
- Uventa stent, 197–198
- Wallstent, 193
- wider lumen stents, 192
- metal ureteral stents, 92
- metoclopramide, 36–37
- migrated and fragmented JJ stent, 227–228
- migrated ureteric stent removal, 209
- modified polyurethanes and proprietary materials, 86–87
- mPEG-DOPA, 105

**n**
- nephrostomy and stenting, 290–291
- nerves, 4
- nitric oxide (NO), 21
- non-bacterial based indwelling device encrustation, 217–218
- non-bacterial causes of encrustation, 216–217
- non-urologic malignancies, 50

**o**
- obstructive nephropathy
  - endothelin-1, 21
  - events in unilateral ureteric obstruction, 20
  - inflammatory cells, 22
  - inflammatory cytokines, 21
  - nitric oxide, 21
  - renal blood flow, GFR and tubular pressure, 20–21
  - tubular cell death, 23–24
  - tubulo-interstitial fibrosis, 23–24
  - tubulo-interstitial inflammation, 22–23
- obstructive pyelonephritis, 68
- obstructive uropathy
  - acute, 19
  - chronic, 19–20
- one-stage antegrade stent, 61–62
- *Oxalobacter formigenes*-derived enzymes, 104

**p**
- palliative care teams, 132
- parenchymal damage and functional loss, 25
- Passager stent, 198
- Paterson-Forrester stent, 151–152
  - detour extra-anatomical ureteric stent, 161–162
  - removal, 208
- patient desire, 132
- patient status, family and social issues, 132
- Pentosan polysulphate (PPS), 104
- Percuflex® stents, 94
- Percuflex Plus® stents, 94
- percutaneous nephrolithotomy (PCNL), 274, 275
- pharmacological agents, 241
- phosphorylcholine, 103
- physical characteristics of stents
  - anti-reflux, 96–97
  - comfort/convenience, 94–95
  - dissolvable stent, 96
  - drainage, 96
  - film-anchoring stent, 98
  - history, 91
  - ketorolac-loaded stent, 99
Index

long-term use, 92–94
self-expanding, 97
spiral stent, 98
standard, 92
thermo-expanding, 97

physiology
anatomical and functional studies, 32–33
effect of acid-base changes, 40–42
effect of metoclopramide and glucagon, 36–37
effect of prostaglandin synthetase inhibitors, 37–39
effects of stents, 42–43
extracorporeal shockwave lithotripsy, 29
invasive ureteric stenting, 30
medical expulsive therapy, 30
pain and myths of ureteric colic, 31–32
physiological and pharmacological properties, 35–36
ureteric colic, 29
ureteric transport mechanisms, 33–35

PICOT framework, 267
pigtail retentive coil, 80
PLA stents, 184
PNNMedical Memokath® stent, 241
Polaris™, 94
Polaris®, 240
polyactic acid (PLA), 88
polyglycolic acid, 183
polymer stents, 92
polyurethane, 85–86
polyvinyl pyrrolidone (PVP) coated stents, 103
post obstructive diuresis, 25–26
post-ureteroscopy stenting, 288
pregnancy, 52
primary carcinoma, 50
prostaglandin synthetase inhibitors, 37–39
Prostakath stent, 193
Prune belly syndrome, 49
psoas hitch, 281–282
PUJ obstruction, 6–7

q
quadra-coil multi-length ureteral stent, 86
quality of life (QOL), 71

r
randomized controlled trials (RCTs), 264–267
removal of ureteric stents
allium, 206
antibiotic prophylaxis, 210
crusted stents, 209–210
extraanatomical stents, 208
healthcare systems, 211
ileal conduit stents, 210
illuminating stents, 208
imaging, 203–204
indwelling time, 203
memokath stent, 205–207
migrated ureteric stents, 209
patient reluctance, 210
resonance stent, 206–207
string, 204–205
technical considerations, 208–209
technique, 204
ureteric injury, 203
uventa stent, 206
rendezvous procedure, 62–64
Resonance stent, 92–93, 196
removal, 206–207
reto-caval ureter, 4–6
retrograde pyelography, 18
retroperitoneal fibrosis (RPF), 51–52
robotic ureteric reconstruction
Boari flap, 282–283
general considerations, 278–279
psoas hitch, 281–282
ureteroneocystostomy, 279–281
ureteroureterostomy, 284

s
salvage therapy options, 131
segmental stents, 296
self-expanding stents, 97
self-reinforced poly-L-lactic and poly-L-glycolic acid (SR-PLGA), 184
semi-rigid/flexible ureteroscope, 126
7/3Fr Tail stents, 96
shock wave lithotripsy (SWL), 10
silicone and silitek, 85
silicone tube, 77–78
6F/10F dual lumen catheter, 177
6 French 22cm Flexima Ureteric Stent System, 59
Sof-Flex®, 86
spiral stent, 98
SpiroFlow stent, 221
SR-PLGA biodegradable stent, 221
S-shaped metal catheter, 76
standard floppy tip polytetrafluoroethylene, 138
standard 7Fr pigtail stent, 96
stent coatings
  antibiotic coatings, 104–105
  antibiotics, 218–219
  antimicrobial peptides, 220
  Bmap-28, 220–221
diamond-like carbon, 103–104
  Foley catheters, 222
glycosaminoglycan hyaluronic acid, 219
glycosaminoglycans, 104
  heparin, 219
  hydrophilic coatings, 102–103
  hydrophilic cross-linked polymer, 219
  iontophoresis, 222
  L-lactide-glycolidic acid co-polymer stent, 221
  mPEG-DOPA, 105
  phosphorylcholine, 103, 220
  silicone, 221
  silver, 220
  SpiroFlow stent, 221
  SR-PLGA biodegradable stent, 221
  urinary citrate, 223
stent design, 60–61
stent insertion procedure
  bladder puncture, 155–156
  kidney aspect, 153–154
stent migration
  ante-grade insertion, 229
detection, 232
distal migration, 229–230
etiology, 231
extra-corporeal shockwave lithotripsy, 229
inadvertent selection, 228
incorrect placement, 227
length and migration, 231
management, 232–233
Memokath stents, 233
metallic stents, 234
migrated and fragmented JJ stent, 227–228
proximal migration, 229–230
segmental stents and migration, 231
stent diameter, material and risk of migration, 231
stent obstruction, 158–159
stent pusher, 77–78
stent register, 120
stent removal forceps, 206

T
Tail stent, 95
tandem ureteral stents
  cost considerations, 179–180
  failure and corrective measures, 175–176
  limited evidence, 178–179
  pathway between, 176–177
  technique, 177–178
technetium99m-mercaptoacetyltriglycine (MAG3), 18
tecoflex, 86
Temporary Ureteral Drainage Stent™, 185
Tetrodotoxin, 36
thermo-expandable stent, 97
32F Amplatz sheath, 161, 163
3F Microstent, 98
tissue engineered ureteral stents, 187
tortuous hydroureter, 139
triclosan, 105
tubeless percutaneous nephrolithotomy, 274–275
tubular cell death, 23–24
tubulo-interstitial fibrosis, 23–24
tubulo-interstitial inflammation, 22–23
21-G introducer needle, 59–60

U
ultrasound (US), 18
uncomplicated ureteroscopy, 289
unilateral subcutaneous stent, 149–150
unilateral ureteric obstruction (UUO), 20–21
upper tract obstruction
  aetiology, 16–17
  anatomical imaging, 18
functional studies, 18–19
obstructive nephropathy, 20–24
obstructive uropathy, 19–20
post-obstructive outcomes, 24–26
presentation, 17
upper tract urothelial carcinoma (UTUC), 50
urease, 216
ureteral catheters, 140–141
ureteral metal stents, 110
ureteral stent materials
autologous and engineered tissue, 88
biodegradable materials and changes in design, 88
biomaterials, 84
coatings, 87–88
metallic stents, 87
modified polyurethanes and proprietary materials, 86–87
design, 88
polyurethane, 85–86
silicone and silitek, 85
soft/flexible materials, 83
vulcanized rubber catheters, 83
ureteric colic, 29
pain and myths of, 31–32
ureteric diverticulae, 8
ureteric stent extraction, post-procedural considerations and cost, 292–293
Ureteric Stent Symptom Questionnaire (USSQ)
development of, 239–240
for when stented, 242, 253–261
for when stent in situ, 242–252
ureteric stricture, 50–51
ureteric transport mechanisms, 33–35
ureteric valves, 49
ureterocele, 12–13
and ureterovesical reflux, 48
ureteroceles, 8
ureterolithiasis, 49–50
ureteroneocystostomy (UNC)
literature, 281
pathology, 279
patient positioning and port placement, 280
procedure, 280–281
ureteropelvic junction (UPJ) obstruction, 49
ureteroscopy and post-procedure stent insertion, 271–274
ureteroureterostomy, 284
Urigo, 208
urinary citrate, 223
Uriprene™, 88, 96, 186–187
uro-lithiasis, 122
urology, 113–115
Urolume prostatic stent, 193
Uromax balloon, 206–207
urothelial cell carcinoma (UCC), 50
Urovision® stent, 241
USSQ. see Ureteric Stent Symptom Questionnaire (USSQ)
Uventa stent, 113–115, 197–198
uventa stent removal, 206

V
vesicoureteric reflux (VUR), 48

W
Wallstent, 193

Z
Zotarolimus-eluting stent, 106